論文（2010）

英文原著

  • Sakai K, Kawata E, Ashihara E, Nakagawa Y, Yamauchi A, Yao H, Nagao R, Tanaka R, Yokota A, Takeuchi M, Hirai H, Kimura S, Hirashima M, Yoshimura N, Maekawa T. Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis. Eur J Immunol 41: 67-75, 2010.
  • Hamaguchi M, Seno T, Yamamoto A, Kohno M, Kadoya M, Ishino H, Ashihara E, Kimura S, Tsubakimoto Y, Takata H, Yoshikawa T, Maekawa T, Kawahito Y. Loxoprofen Sodium, a Non-Selective NSAID, Reduces Atherosclerosis in Mice by Reducing Inflammation. J Clin Biochem Nutr 47: 138-147, 2010.
  • Tanaka M, Fukushima N, Yamasaki F, Ohshima K, Sueoka E, Kimura S. Primary hepatic extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue type is associated with chronic inflammatory process. Open J Hematol 1-5, 2010.
  • Ureshino N, Aragane N, Nakamura T, Ide M, Mochinaga S, Fukushima N, Hayashi S, Sueoka E, Kimura S. A Fully Integrated and Automated Detection System for Single Nucleotide Polymorphisms of UGT1A1 and CYP2C19. Oncol Res, in press.
  • Kuroda J, Kobayashi T, Nagoshi H, Yamamoto M, Sasaki N, Taki T, Kimura S, Yamauchi A, Hirashima M, Taniwaki M. Targeting ATF-3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol Cancer Res 8: 994-1001, 2010.
  • Ushiki T, Kimura S, et al. Noninvasive tracking of donor cell homing by near-infrared fluorescence imaging shortly after bone marrow transplantation. PLoS One 5: e11114, 2010.
  • Ryu K, Murata H, Koto K, Horie N, Matsui T, Nishigaki Y, Sakabe T, Takeshita H, Itoi M, Kimura S, Ashihara E, Maekawa T, Fushiki S, Kubo T. Combined effects of bisphosphonate and radiation on osteosarcoma cells. Anticancer Res 30: 2713-2720, 2010.
  • Koto K, Murata H, Kimura S, Horie N, Matsui T, Nishigaki Y, Ryu K, Sakabe T, Ashihara E, Maekawa T, Fushiki S, Kubo T. Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents. Oncol Rep 24: 233-239, 2010.
  • Tanaka R, Squires MS, Kimura S, Yokota A, Nagao R, Yamauchi T, Takeuchi M, Yao H, Reule M, Smyth T, Lyon JF, Thompson NT, Ashihara E, Ottmann OG, Maekawa T. Activity of the multi-targeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL positive leukemic cells. Blood 116: 2089-2095, 2010.
  • Ide M, Kuwahara N, Matsuishi E, Kimura S, Gondo H. Uncommon case of chronic myeloid leukemia with multiple myeloma. Int J Hemmatol 91: 699-704, 2010.
  • Kawata E, Ahihara E, Nakagawa Y, Kiuchi T, Ogura M, Yao H, Sakai K, Tanaka R, Nagao R, Yokota A, Takeuchi M, Kimura S, Hirai H, Maekawa T. A combination of a DNA-chimera 1 siRNA against PLK-1 and zoledronic acid suppresses the growth of malignant mesothelioma cells in vitro. Cancer Lett 294: 245-53, 2010.
  • Takeuchi M, Kimura S, Kuroda J, Ashihara E, Kawatani M, Osada H, Umezawa K, Yasui E, Imoto M, Tsuruo T, Yokota A, Tanaka R, Nagao R, Nakahara T, Fujiyama Y, Maekawa T. Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in hypoxic environment. Cell Death Diff 17: 1211-1220, 2010.
  • Tanaka M, Fukushima N, Urata C, Yokoo M, Ide M, HIsatomi T, Tomimasu R, Sueoka E. Gangrenous cheilitis associated with all-trans retinoic acid therapy for acute promyelocytic leukemia. Int J Hematol 91: 132-135, 2010.
  • Kei-ichi Ozaki, Masaki Kosugi, Nobuyuki Baba, Keisuke Fujio, Toshiaki Sakamoto, Shinya Kimura, Susumu Tanimura, Michiaki Kohno. Blockade of the ERK or PI3K–Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib. Biochem Biophys Res Commun 391: 1610-1615, 2010.
  • Kantarjian H, le Coutre P, Cortes J, Pinilla-lbarz J, Nagler A, Hochhaus A, Kimura S, Ottmann O. Phase I study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias post-imatinib resistance or intolerance. Cancer 116: 2665-72, 2010.
  • Yokota A, Kimura S, Tanaka R, Takeuchi M, Yao H, Sakai K, Nagao R, Kuroda J, Kamitsuji Y, Kawata E, Ashihara E, Maekawa T. Osteoclasts are involved in the maintenance of dormant leukemic cells. Leuk Res 34: 793–799, 2010.
  • Ito K, Aoyama T, Fukiage K, Otsuka S, Furu M, Jin Y, Nasu A, Ueda M, Kasai Y, Ashihara E, Kimura S, Maekawa T, Kobayashi A, Yoshida S, Otsuka T, Nakamura T, Toguchida J. Isolation of mesenchymal stem cells from bone marrow in the closed system using a new device made by non-woven fabrics. Tissue Eng Part C Methods 16: 81-91, 2010.
  • Hisatomi T, Sueoka-Aragane N, Sato A, Tomimasu R, Ide M, Kurimasa A, Okamoto K, Kimura S, Sueoka E. NK314 potentiates anti-tumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase IIa and DNA-dependent protein kinase. Blood, in press.
  • Komiya K, Sueoka-Aragane N, Sato A, Hisatomi T, Sakuragi T, Mitsuoka M, Sato T, Hayashi S, Izumi H, Tsuneoka M, Sueoka E. Mina53, a novel c-Myc target gene, is frequently expressed in lung cancers and exerts oncogenic property in NIH/3T3 cells. J Cancer Res Clin Oncol 136: 465-473, 2010.
  • Komiya K, Sueoka-Aragane N, Sato A, Hisatomi T, Sakuragi T, Mitsuoka M, Sato T, Hayashi S, Izumi H, Tsuneoka M, Sueoka E. Expression of Mina53, a novel c-Myc target gene, is a favorable prognostic marker in early stage lung cancer. Lung Cancer 69: 232-238, 2010.
  • Ozaki K, Kosugi M, Baba N, Fujio K, Sakamoto T, Kimura S, Tanimura S, Kohno M. Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib. Biochem Biophys Res Commun 391: 1610-1615, 2010.

英文総説

  • Kimura S. Second Generation Abl Kinase Inhibitors and Novel Compounds to Eliminate the Bcr-Abl/T315I Clone (Second Edition). Frontiers in Anti-Cancer Drug Discovery 1: 116-131, 2010.
  • Kimura S. AT-9283, a small molecule multi-targeted kinase inhibitor for the treatment of cancer. Curr Opin Investig Drugs 11: 1442-1449, 2010.

邦文原著

  • 村松裕子、木村晋也、一戸辰夫、芦原英司、石川隆之、前川 平、内山 卓. 造血幹細胞移植における血縁ドナーのための専門外来. 日本輸血細胞治療学会誌 56: 68-71, 2010.
  • 福島伯泰、木村晋也. 【学会印象記】第51回米国血液学会. 血液フロンティア 20: 610-612, 2010.

邦文著書

  • 福島伯泰、末岡榮三朗. B細胞性小型リンパ球腫瘍の診断のコツとその治療. 症例検討を通して学ぶ悪性リンパ腫診療の実際－リンフォーマ井戸端会議から学んだこと－. メディカルレビュー社, 85-89.
  • 福島伯泰、末岡榮三朗. Indolent lymphomaからの形質転換について. 症例検討を通して学ぶ悪性リンパ腫診療の実際－リンフォーマ井戸端会議から学んだこと－. メディカルレビュー社, 130-134.

邦文総説

  • 出勝、木村晋也. 慢性骨髄性白血病の治療‐治癒を目指して. 日本医事新報 4516: 50-54,
  • 木村晋也. ABLチロシンキナーゼ阻害剤の新展開. 臨床血液 51: 597-604, 2010.
  • 福島伯泰、木村晋也. チロシンキナーゼ阻害剤によるBCL-ABL白血病の治療. 血液フロンティア 20: 1464-1470, 2010.
  • 木村晋也. 慢性白血病における最近の薬物療法の進歩. Medical Science Digest 36: 12-15, 2010
  • 木村晋也. 分子標的薬はなぜ「がん」に有効か. 日本染色体遺伝子学会雑誌 28: 13-19, 2010.
  • 福島伯泰、木村晋也. 血液癌における分子標的薬の現状と今後の課題. Drug Delivery System 25: 126-133, 2010.
  • 福島伯泰、木村晋也. ポスト・イマチニブ時代. 日本内科学会雑誌 99: 1072-1079, 2010.
  • 木村晋也. ゾレドロン酸とγδ T cell activation. Pharma Medica 28: 19-24, 2010.
  • 田中真理子、木村晋也. Ph陽性急性リンパ性白血病　分子標的薬はこの難治性疾患の予後をどう変えるか. Medical Practice 27: 313-316, 2010.
  • 高橋浩一郎、林真一郎. 胸膜炎・膿胸と抗菌薬の選択. 化学療法の領域 26：1879-1885, 2010.

最終更新日：2014年10月1日

(C)佐賀大学医学部附属病院血液・呼吸器・腫瘍内科